Evidence map›Paper›PMID 40270785›Full record

ArticleJournal of immunotherapy and precision oncology2025

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.

Karen A Autio, Deaglan J McHugh, Dana E Rathkopf, Han Xiao, Swathi Merugu, Phillip Wong, Mehrin Jan, Tanya B Dorff, Elisabeth I Heath, Howard I Scher

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunotherapy and precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Karen A AutioGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID https://orcid.org/0000-0003-0720-0390
Deaglan J McHughGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dana E RathkopfGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Han XiaoGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Swathi MeruguImmune Monitoring Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Phillip WongImmune Monitoring Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mehrin JanGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tanya B DorffDepartment of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Elisabeth I HeathKarmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Howard I ScherGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ADTbiochemical recurrenceimmunotherapyPARP inhibitorprostate cancer

Identifiers

PMID40270785
PMCPMC12010483

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.